Several mechanisms of trastuzumab resistance have been identified in breast cancer, one of which is increased signaling through the PI3-kinase pathway caused by gain-of-function PIK3CA mutations or inactivation of PTEN [36]. This evidence concerns the gene PIK3CA and breast carcinoma.